Clinical Research Directory
Browse clinical research sites, groups, and studies.
Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
Sponsor: COMPASS Pathways
Summary
The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.
Official title: A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
300
Start Date
2026-09
Completion Date
2029-09
Last Updated
2026-10-06
Healthy Volunteers
No
Conditions
Interventions
COMP360 psilocybin
COMP360 psilocybin administered with monitoring and support
Locations (8)
FL
Miami, Florida, United States
FL
Orlando, Florida, United States
IL
Chicago, Illinois, United States
MN
Eden Prairie, Minnesota, United States
NE
Lincoln, Nebraska, United States
NV
Las Vegas, Nevada, United States
NY
New York, New York, United States
BC
North Vancouver, British Columbia, Canada